Effect of convalescent plasma in patients with severe COVI-19

Not Applicable

Recruiting

• Conditions: Coronavirus infection; Sepsis; C01.925.782.600.550.200; C01.757

• Registration Number: RBR-4vm3yy
• Lead Sponsor: Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-15
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Age > or equal to 18 years; Severe or critical-19 COVID-19; Length of stay < 3 days; Laboratory confirmation of COVID-19 by detection of the viral genome in respiratory secretions, collected by swab; Signature, by the patient or a relative, of the informed consent form

Exclusion Criteria

Allergic reactions prior to plasma transfusion

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Temporal improvement in inflammatory biomarkers and organ dysfunction scores during ICU admission, measured by the daily reduction in 10% of biomarkers in plasma and respiratory secretions, per day for 14 days <br><br>

Secondary Outcome Measures

Name	Time	Method
Reduction of 10% in mechanical ventilations days, measured by ventilation-free days during the first 14 days<br><br>;Reduction of 5% in in-hospital mortality, measured by the frequency of deaths during hospital admission<br><br>;Reduction of 10% in ICU length of stay, measured by days of ICU and hospital admission<br><br>